INFOGRAPHIC: 72 US IPOs gross $5.7bn in 2014; values rising in 2015

In 2014, 72 biotechnology firms that develop drugs, biologics and gene, stem or cell therapies grossed $5.7bn from initial public offerings in the US with most companies ending the year with stock values well above their IPO price – and values have risen higher in 2015.